View Older Stories View More Recent Stories

Nov 10, 2017 10:30AM Sunovion Announces FDA Acceptance for Review of New Drug Application for Dasotraline for the Treatment of ADHD
Oct 31, 2017 08:00AM Sunovion Presents New Phase 3 Study Analyses Supporting Safety and Efficacy of SUN-101/eFlow® (glycopyrrolate) for the Treatment of COPD
Oct 27, 2017 04:00PM Sunovion Presents Data from Phase 3 Studies of Latuda® (lurasidone HCl) in Children and Adolescents with Bipolar Depression
Oct 24, 2017 08:00AM Sunovion to Present Data on Nebulized Treatment Options for COPD at the American College of Chest Physicians® (CHEST) Annual Meeting 2017
Oct 19, 2017 08:11AM Sunovion Announces Seebri™ Neohaler® (glycopyrrolate) Inhalation Powder is Now Available in the United States
Sep 14, 2017 12:20PM Sunovion’s Aptiom® (eslicarbazepine acetate) Receives FDA Approval for Expanded Indication to Treat Partial-Onset Seizures in Children and Adolescents 4 Years of Age and Older
Sep 14, 2017 08:00AM Sunovion to Present Data Across Multiple Psychiatric Conditions at the 2017 Psych Congress
Aug 31, 2017 08:00AM Sunovion Submits New Drug Application for Dasotraline to the FDA for the Treatment of Patients with ADHD
Aug 7, 2017 12:40PM Monsanto and Valent U.S.A. LLC Announce Expanded Partnership in Roundup Ready PLUS® Crop Management Solutions
Jul 21, 2017 11:30AM Sunovion’s Latuda® (lurasidone HCI) Receives Health Canada Approval to Treat Adolescents with Schizophrenia
Jul 18, 2017 11:36AM Sunovion Expands Commitment to Building Stronger Communities through Partnerships with the Red Sox Foundation, United Way of Tri-County and Bergen Volunteer Center
Jul 13, 2017 08:00AM Sunovion Enters Agreement to Divest Asthma and Allergy Products to Covis Pharma
Jun 30, 2017 08:05AM Sunovion Announces FDA Acceptance for Review of Supplemental New Drug Application for Latuda® (lurasidone HCI) for the Treatment of Bipolar Depression in Children and Adolescents
Jun 30, 2017 08:00AM Sunovion Announces FDA Acceptance for Review of New Drug Application Resubmission for SUN-101/eFlow® (glycopyrrolate) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
May 26, 2017 06:45PM Sunovion Receives Complete Response Letter from FDA for SUN-101/eFlow® (glycopyrrolate) New Drug Application for Chronic Obstructive Pulmonary Disease (COPD)
May 23, 2017 11:00AM Sunovion Announces Positive Results from Pivotal Study Evaluating Novel Drug Candidate Dasotraline in Adults with Binge Eating Disorder at Annual American Psychiatric Association Meeting
May 23, 2017 09:18AM Sunovion Announces Utibron™ Neohaler® (indacaterol/glycopyrrolate) Inhalation Powder Data Showing Lung Function and Health-Related Quality of Life Improvement in Patients with Moderate-to-Severe Ch
May 23, 2017 09:15AM Sunovion Presents Phase 3 Data Showing Safety, Efficacy and Improvement in Quality of Life Outcomes in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease Treated with SUN-101/
May 22, 2017 11:00AM Sunovion Announces Positive Results from Study Evaluating Latuda® (lurasidone HCl) in Children and Adolescents with Bipolar Depression at Annual American Psychiatric Association Meeting
May 22, 2017 08:00AM U.S. FDA Accepts for Review Supplemental New Drug Application for Aptiom® (eslicarbazepine acetate) for the Treatment of Partial-Onset Seizures in Children 4 to 17 Years of Age
May 16, 2017 08:00AM Sunovion Data Presentations at Annual American Psychiatric Association Meeting Showcase Growing Psychiatry Franchise
May 15, 2017 08:15AM Sunovion to Present Clinical Efficacy, Safety and Health-Related Quality of Life Outcomes Data from Its Respiratory Franchise at the American Thoracic Society 2017 International Conference
Apr 21, 2017 11:00AM Sunovion Announces Positive Results from Pivotal Study Evaluating Novel Drug Candidate Dasotraline in Children with ADHD
Apr 19, 2017 08:00AM Sunovion to Present Data on Aptiom® (eslicarbazepine acetate) at the American Academy of Neurology 2017 Annual Meeting
Apr 3, 2017 08:00AM Sunovion Announces Utibron™ Neohaler® (indacaterol/glycopyrrolate) Inhalation Powder Now Available in the United States
Mar 31, 2017 08:00AM Sunovion to Present Data on LATUDA® (lurasidone HCI) at the 25th European Congress of Psychiatry
Mar 13, 2017 09:00AM Sunovion Submits Supplemental New Drug Application to FDA for Use of APTIOM® (eslicarbazepine acetate) for the Treatment of Partial-Onset Seizures in Children 4 Years of Age and Older
Feb 27, 2017 08:00AM Sunovion Announces Positive Topline Results from Study Evaluating Latuda® (lurasidone HCl) in Children and Adolescents with Bipolar Depression
Feb 22, 2017 08:00AM Demi Lovato, Sunovion and Leading Advocacy Organizations Release Mental Health Documentary as Part of Be Vocal Initiative
Jan 28, 2017 09:30AM Sunovion’s Latuda® (lurasidone HCl) Receives FDA Approval to Treat Adolescents with Schizophrenia
Jan 14, 2017 11:31AM Sunovion Announces Pivotal Study Results for Novel Drug Candidate Dasotraline Demonstrating Significantly Improved Attention Deficit Hyperactivity Disorder Symptoms in Children Compared to Placebo
Jan 13, 2017 08:30AM Sunovion Announces Top-line Results from Studies Evaluating Dasotraline in Adults with Binge Eating Disorder and Attention Deficit Hyperactivity Disorder
Dec 21, 2016 08:00AM Sunovion Enters into License Agreement for Three Approved Treatment Options for People with COPD in the U.S.
Dec 15, 2016 08:00AM Sunovion Announces Collaboration with AMDA – The Society for Post-Acute and Long-Term Care Medicine
Dec 4, 2016 08:00AM Sunovion to Initiate Recruitment for Aptiom® (eslicarbazepine acetate) Clinical Study with Integrated Digital Health Technology to Aid Seizure Detection
Dec 2, 2016 08:00AM Sunovion Initiates SEP-363856 Phase 2 Program for Patients with Schizophrenia or Parkinson’s Disease Psychosis
Dec 2, 2016 08:00AM Sunovion to Present Data on Latuda® (lurasidone HCl) and Novel Investigational Psychotropic SEP-363856 at the 55th Annual Meeting of the American College of Neuropsychopharmacology
Nov 30, 2016 08:00AM Demi Lovato, Sunovion and Leading Advocacy Organizations Launch The Be Vocal Collection in Partnership with Getty Images to Encourage the Realistic Portrayal of Mental Health
Nov 28, 2016 08:01AM Sunovion Presents Clinical and Health Economics Outcome Research Data for Aptiom® (eslicarbazepine acetate) at the American Epilepsy Society (AES) 70th Annual Meeting
Nov 1, 2016 09:30AM Sunovion Recognizes Epilepsy and COPD Awareness Months in the U.S. During November
Oct 27, 2016 08:00AM Sunovion Announces Positive Clinical Study Results for Latuda® (lurasidone HCl) in Adolescents with Schizophrenia
Oct 21, 2016 09:50AM Sunovion Pharmaceuticals Completes Acquisition of Cynapsus Therapeutics
Oct 20, 2016 10:00AM The American College of Chest Physicians and Sunovion Announce Strategic Initiative Focused on the Importance of Drug Delivery in the Management of COPD
Oct 13, 2016 08:00AM Sunovion Announces FDA Filing Acceptance of New Drug Application for SUN-101/eFlow® for the Treatment of Patients with Chronic Obstructive Pulmonary Disease (COPD)
Sep 28, 2016 07:27PM ISS Recommends Cynapsus Therapeutics Securityholders Vote for the Plan of Arrangement
Sep 20, 2016 08:00AM Sunovion Announces Results from Pivotal Study Evaluating Novel Drug Candidate Dasotraline in Children with ADHD
Sep 16, 2016 10:54AM Sunovion to Present Data on Latuda® (lurasidone) at the 29th European College of Neuropsychopharmacology (ECNP) Congress
Aug 31, 2016 05:08PM Sunovion Pharma to Acquire Cynapsus Therapeutics (CYNA) in ~$624M Deal
Aug 31, 2016 05:07PM Sunovion Pharmaceuticals to Acquire Cynapsus Therapeutics
Aug 24, 2016 02:00AM Pfizer to Acquire Small Molecule Anti-Infective Business from AstraZeneca
View More Recent Stories View Older Stories